INSULET CORP

Insulet Corporation (NASDAQ: PODD) develops, manufactures, and sells proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The company's website is www.insulet.com.

The Omnipod platform represents the core of Insulet's business and includes three primary products: Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, and Classic Omnipod. Omnipod 5, cleared by the FDA in 2022 and available in 19 countries, features a proprietary automated insulin delivery algorithm embedded in a small, disposable pod that integrates with continuous glucose monitors from Dexcom and Abbott to automatically adjust insulin dosing. Omnipod DASH offers wireless Bluetooth-enabled pod technology controlled through a personal diabetes manager device with touchscreen interface. The company also manufactures pods for Amgen used in the Neulasta Onpro kit for chemotherapy patients.

Insulet's tubeless, waterproof pod design can be worn for up to three days in multiple body locations and eliminates the need for external tubing required by conventional insulin pumps. The company markets its products as offering unprecedented freedom and convenience for diabetes management compared to multiple daily injections or traditional pump therapy.

Omnipod products are currently available in 25 countries across North America, Europe, the Middle East, and Asia-Pacific regions. For the year ended December 31, 2025, approximately 86 percent of Omnipod product sales globally were through intermediaries, with three major distributors accounting for 78 percent of total revenue. The company maintains manufacturing facilities in Acton, Massachusetts and Johor, Malaysia, with a third facility under development in Costa Rica. As of December 31, 2025, Insulet employed approximately 5,400 full-time employees, representing a 38 percent increase from the prior year, with approximately 60 percent located in the United States and the remainder across 17 other countries.

The company holds over 1,000 patents in the United States and other countries with expiration dates through 2047, covering the Omnipod drive system, cannula insertion system, software algorithms, and various delivery mechanisms. Insulet maintains registered trademarks including Omnipod, Omnipod DASH, and Omnipod Discover.